Valneva
Valneva SE is a specialty vaccine company dedicated to the development and commercialization of vaccines for infectious diseases that have significant unmet needs. The company offers two commercial vaccines for travelers: IXIARO/JESPECT, which prevents Japanese encephalitis, and DUKORAL, which is used to prevent cholera and certain types of diarrhea. Valneva is also advancing a diverse pipeline of vaccine candidates, including a unique vaccine for Lyme disease and a single-shot vaccine for chikungunya. Headquartered in Nantes, France, Valneva operates in several countries including Austria, Canada, France, Sweden, the United Kingdom, and the United States. Additionally, the company collaborates with Dynavax Technologies Corporation to enhance the development of its COVID-19 vaccine. Established in 1999, Valneva continues to focus on addressing critical public health challenges through innovative vaccine solutions.
Crucell Sweden is a company engaged in the development, manufacturing, and distribution of vaccines and antibodies aimed at preventing and treating infectious diseases. It offers contract manufacturing services to vaccine companies both in Sweden and internationally, producing biological bulk and active pharmaceutical ingredients (APIs), as well as finished products for clinical trials and market supply. Through its comprehensive capabilities, Crucell Sweden plays a vital role in the biotechnology sector, supporting the advancement of vaccine development and production.
BliNK Biomedical SAS is a biotechnology company based in Lyon, France, founded in 2014. The company specializes in the discovery and development of monoclonal antibodies aimed at treating life-threatening diseases, particularly in the field of immuno-oncology. Its lead program focuses on a monoclonal antibody that targets an immune checkpoint, enhancing the body's immune response against tumors. BliNK Biomedical employs a unique B cell technology platform that facilitates the selection and isolation of specific antibody-producing cells from various species, including humans and animals. This innovative approach allows researchers to efficiently identify and develop next-generation anti-tumor therapeutics targeting novel immuno-oncology and immune-checkpoint pathways.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.